Filing Flows › Editas Medicine (EDIT) › R&D spending
Editas Medicine (EDIT) R&D spending by quarter
Editas Medicine's R&D spending was $17.6M in Q1 2026 (first quarter 2026), -11% from Q3 2025. Over the last 5 quarters it ranged from $16.2M (Q2 2025) to $48.6M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $17.6M | -11% | -34% |
| Q3 2025 | $19.8M | +22% | — |
| Q2 2025 | $16.2M | -39% | — |
| Q1 2025 | $26.6M | -45% | — |
| Q4 2024 | $48.6M | — | — |
Q1 2026 at a glance
Editas Medicine, Q1 2026: revenue $2.8M (-39% year over year), operating margin -883.2%, net loss $25.0M, operating cash flow −$23.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Editas Medicine's R&D spending?
Editas Medicine's R&D spending was $17.6M in Q1 2026 (first quarter 2026), -11% from Q3 2025.
How has Editas Medicine's R&D spending changed?
Over the last 5 quarters it ranged from $16.2M (Q2 2025) to $48.6M (Q4 2024).